{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:30:21Z","timestamp":1789587021622,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.bmc.2021.116291","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:41:36Z","timestamp":1624520496000},"page":"116291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Design, synthesis and biological evaluation of double fatty chain-modified glucagon-like peptide-1 conjugates"],"prefix":"10.1016","volume":"44","author":[{"given":"Jinhua","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzhen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianwen","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2021.116291_b0005","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.peptides.2017.12.021","article-title":"Gut hormone polyagonists for the treatment of type 2 diabetes","volume":"100","author":"Brandt","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.bmc.2021.116291_b0010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.diabres.2017.03.024","article-title":"IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040","volume":"128","author":"Ogurtsova","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.bmc.2021.116291_b0015","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1517\/13543784.2016.1123249","article-title":"An overview of new GLP-1 receptor agonists for type 2 diabetes","volume":"25","author":"Tomlinson","year":"2016","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.bmc.2021.116291_b0020","doi-asserted-by":"crossref","DOI":"10.1111\/j.1432-1033.1993.tb17986.x","article-title":"Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7\u201336) amide, peptide histidine methionine and is responsible for their degradation in human serum","author":"Mentlein","year":"1993","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.bmc.2021.116291_b0025","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0014-5793(87)81430-8","article-title":"Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut","volume":"211","author":"Holst","year":"1987","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bmc.2021.116291_b0030","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s001250050903","article-title":"Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity","volume":"41","author":"Deacon","year":"1998","journal-title":"Diabetologia"},{"key":"10.1016\/j.bmc.2021.116291_b0035","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.2337\/diacare.24.8.1416","article-title":"Glucagon-like peptide-1 infusion must be maintained for 24 h\/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment","volume":"24","author":"Larsen","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bmc.2021.116291_b0040","doi-asserted-by":"crossref","first-page":"6889","DOI":"10.1021\/jm901153x","article-title":"Preparation and structural, biochemical, and pharmaceutical characterizations of bile acid modified long-acting exendin-4 derivatives","volume":"52","author":"Son","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116291_b0045","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/j.jconrel.2009.10.025","article-title":"Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs","volume":"142","author":"Chae","year":"2010","journal-title":"J Control Release"},{"key":"10.1016\/j.bmc.2021.116291_b0050","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1006\/jmbi.2000.4158","article-title":"Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin","volume":"303","author":"Bhattacharya","year":"2000","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bmc.2021.116291_b0055","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1021\/jm9909645","article-title":"Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration","volume":"43","author":"Knudsen","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116291_b0060","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1021\/jm070861j","article-title":"Structure activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness","volume":"50","author":"Madsen","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116291_b0065","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116291_b0070","first-page":"4","article-title":"Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity","volume":"4","author":"Gianluca","year":"2020","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.bmc.2021.116291_b0075","first-page":"1","article-title":"Semaglutide versus dulaglutide: SUSTAIN 7-a head-to-head trial in patients with type 2 diabetes","author":"Federbusch","year":"2018","journal-title":"Der Diabetologe."},{"key":"10.1016\/j.bmc.2021.116291_b0080","doi-asserted-by":"crossref","first-page":"cd180034","DOI":"10.2337\/cd18-0034","article-title":"Oral Semaglutide","volume":"36","author":"Bui","year":"2018","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.bmc.2021.116291_b0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP And GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metabolism"},{"key":"10.1016\/j.bmc.2021.116291_b0090","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2021.116291_b0095","unstructured":"Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes, News provide by Eli Lilly and Company, Mar 04, 2021. https:\/\/www.prnewswire.com\/news-releases\/."},{"key":"10.1016\/j.bmc.2021.116291_b0100","doi-asserted-by":"crossref","first-page":"9955","DOI":"10.1021\/jm4017448","article-title":"Design, synthesis, and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates","volume":"56","author":"Han","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116291_b0105","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1016\/j.bmc.2018.04.022","article-title":"Novel fatty acid chain modified GLP-1 derivatives with prolonged in vivo glucose-lowering ability and balanced glucoregulatory activity","volume":"26","author":"Cai","year":"2018","journal-title":"Bioorg Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621002996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621002996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:13:08Z","timestamp":1760836388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089621002996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":21,"alternative-id":["S0968089621002996"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116291","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of double fatty chain-modified glucagon-like peptide-1 conjugates","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116291","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116291"}}